anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Sequoia Pitch

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 43,093
Current window 23,671-23,700
Pages 1,437
Rows per page 30
Arc: Sequoia Pitchclear collectionreset all
18 30 60

Arc

23,671-23,700 of 43,093

filter-aware
25
The slide uses a combination of high-level market statistics and specific clinical benchmarks to define the target opportunity.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
26
The chart highlights a specific patient case with a partial response (PR) and notes a suboptimal dose case.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
27
Uses a 2x2 grid of metrics to frame the problem space.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
28
The chart tracks % change in target lesions over time (weeks) for two specific patients.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
29
The slide uses a funnel-like logic to narrow down from total prevalence to a specific addressable patient population for a 2L+ therapy.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
30
The slide uses a table to present clinical trial outcomes (PR/CR) and safety data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
31
The slide outlines patient enrollment targets and treatment protocols for specific refractory patient populations.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
32
The table compares dosing schedules for a clinical trial drug.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
33
BA3021 Ozuriftamab VedotinBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
34
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
35
The slide uses a combination of a summary table for clinical endpoints and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
36
The slide outlines a dose-escalation study (3+3 design) leading to RP2D selection and subsequent expansion cohorts.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
37
BioAtla | Investor Presentation Deck | 43 slidesBioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
38
The slide uses a before-after-bridge style comparison between the problem (toxicity) and the solution (BA3182).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
39
The slide uses a process flow diagram to illustrate dose escalation strategies (Accelerated vs Standard vs Priming).BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
40
The slide uses a two-column layout to represent 1H and 2H of 2023.BioAtla | Investor Presentation Deck | 43 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
04
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Team1 hit
07
The slide uses a strong visual of the product to establish brand identity.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Solution1 hit
09
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Business ModelLoop · Mece Breakdown1 hit
15
The EBITDA loss range is presented as $27-23 million, which is counter-intuitive ordering (high to low).Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
16
The slide uses a minimalist design with two primary callout boxes representing financial goals.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
18
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
19
Blue Apron | Investor Presentation Deck | 23 slidesBlue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
20
Page number 20 visible in bottom right corner.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
21
The table shows negative cash flow figures for both periods.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
22
The table presents a standard non-GAAP financial reconciliation.Blue Apron | Investor Presentation Deck | 23 slides · Blue Apron
Pitch deck Investor relations Beat · Financials1 hit
04
The slide uses a visual equation (Icon + Icon + Icon) to summarize the business model.Cano Health | Results Presentation Deck | 13 slides · Cano Health
Conference presentation Investor relations Beat · Problem1 hit
05
Uses a standard 5-column pillar layout to summarize the company's value proposition.Cano Health | Results Presentation Deck | 13 slides · Cano Health
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Includes a disclaimer about rounding differences.Cano Health | Results Presentation Deck | 13 slides · Cano Health
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
The slide contains two distinct tables: one for absolute member counts and one for percentage of total members.Cano Health | Results Presentation Deck | 13 slides · Cano Health
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit